Barycela (varicella II vaccine) / GC Biopharma - LARVOL DELTA

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years (clinicaltrials.gov) - P3 | N=474 | Not yet recruiting | Sponsor: GC Biopharma Corp

Head-to-Head • New P3 trial • Infectious Disease • Varicella Zoster

A COMPREHENSIVE REVIEW OF MAV/06 VARICELLA VACCINES: SAFETY, IMMUNOGENICITY, AND EFFECTIVENESS (ESPID 2025) - "Most of the vaccines are based on the Oka strain, while MAV/06 strain vaccines (Varicella Vaccine-GCC inj. and BARYCELA inj.) were exclusively developed by GC Biopharma Corp...Conclusions/Learning Points In terms of safety, immunogenicity, and effectiveness, MAV/06 strain varicella vaccines are comparable to Oka strain varicella vaccines. We expect that MAV/06 vaccines as cost-effective varicella vaccines make a significant contribution to improving global public health and health equality in children."

Clinical • Review • Herpes Zoster • Infectious Disease • Varicella Zoster

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination (clinicaltrials.gov) - P2 | N=230 | Recruiting | Sponsor: Green Cross Corporation | N=501 ➔ 230

Enrollment change • Varicella Zoster

Cross-reactive humoral immunity of clade 2 Oka and MAV/06 strain-based varicella vaccines against different clades of varicella-zoster virus. (PubMed, Hum Vaccin Immunother) - "Nevertheless, the GMTs of the two vaccinated groups for the same strain were not significantly different. These results suggest that both MG1111 and VARIVAX vaccinations induce cross-reactive humoral immunity against other clades of VZV."

Journal • Herpes Zoster • Varicella Zoster

Assessment of attenuation of varicella-zoster virus vaccines based on genomic comparison. (PubMed, J Med Virol) - "To assess the attenuation of commercial VZV vaccines, genetic variants were comprehensively examined through high-throughput sequencing of viral DNA isolated from four VZV vaccines (Barycela, VarilRix, VariVax, and SKY Varicella). In particular, attenuation-associated 42 SNPs showed that Barycela, VarilRix, VariVax, and SKY Varicella are in ascending order regarding similarity with pOka-like genotypes, which in turn, might provide genomic evidence for the levels of attenuation. Finally, the phylogenetic network analysis demonstrated that genetic distances from the parental strain correlated with the attenuation levels of the vaccines."

Journal • Herpes Zoster • Infectious Disease • Varicella Zoster

An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years (clinicaltrials.gov) - P=N/A | N=250 | Not yet recruiting | Sponsor: GC Biopharma Corp

New trial • Herpes Zoster • Infectious Disease • Varicella Zoster

Evaluate the Safety and Immunogenicity After MG1111 as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st SUDUVAX Inj. Vaccination (clinicaltrials.gov) - P2 | N=501 | Recruiting | Sponsor: Green Cross Corporation | Not yet recruiting ➔ Recruiting

Enrollment open • Varicella Zoster

Evaluate the Safety and Immunogenicity After MG1111 as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st SUDUVAX Inj. Vaccination (clinicaltrials.gov) - P2 | N=501 | Not yet recruiting | Sponsor: Green Cross Corporation

New P2 trial • Varicella Zoster

A Study of MG1111 in Healthy Children (clinicaltrials.gov) - P2/3; N=814; Completed; Sponsor: Green Cross Corporation; Recruiting ➔ Completed

Clinical • Head-to-Head • Trial completion

Immunogenicity and safety profiles of a new MAV/06 strain varicella vaccine in healthy children: A multinational, multicenter, randomized, double-blinded, active-controlled phase III study. (PubMed, Vaccine) - "Furthermore, the MG1111 and control vaccine groups were not significantly different in the percentage of participants showing adverse events-solicited, local, or systemic during 43-day period of observation and serious adverse events during 6 month of observation. The present results indicate that MG1111was not immunologically inferior to Varivax, and safety profiles of MG1111 are similar to those of Varivax."

Clinical • Journal • P3 data • Immunology • Varicella Zoster